HXN-1003 / Sanofi, Earendil Labs - LARVOL DELTA

Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel Diseases (PRNewswire) - "Earendil Labs...and Sanofi today announced that they have entered into a license agreement for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases. Under the agreement, Sanofi will obtain exclusive worldwide rights to two bispecific antibodies, HXN-1002 and HXN-1003...As part of the agreement: Earendil Labs will receive an upfront payment of $125 million. Earendil Labs is eligible to receive up to a total of $1.72 billion in development and commercial milestone payments, including a $50 million near-term payment."

Licensing / partnership • Immunology • Inflammatory Bowel Disease